Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Recruiting KRAS to Attack Lung Cancer

Page View:

        Scientists at the University of Texas Southwestern Medical Center say they have identified a new way to target lung cancer through the KRAS (Kirsten rat sarcoma viral oncogene homolog) gene, one of the most commonly mutated genes in human cancer and one researchers have so far had difficulty targeting successfully.

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.


        Investigators studying the underlying biology of KRAS in lung cancer determined that activity resulting from the ACSL3 gene is essential for these lung cancer cells to survive, and that suppressing ACSL3 causes these lung cancer cells to die.


        The study (“Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis”) appears in Cell Reports.


        The findings are significant because genetic mutations of KRAS occur in about 30% of lung cancer cases, and they are associated with aggressive, therapy-resistant disease with a poor prognosis. Lung cancer remains the leading cause of cancer-related deaths in the U.S., according to the National Cancer Institute (NCI).


Related Articles:

British New Lung Cancer Drug Wins Approval in China

Research Reveals Insight into How Lung Cancer Spreads

Liquid Biopsy Better Option for Advanced Lung Cancer Patients

        “Despite some recent advances, mutant KRAS remains a very challenging target. There is a dearth of treatment options for tumors initiated by this gene,” said senior author Pier Paolo Scaglioni, M.D., Associate Professor of Internal Medicine in the Division of Hematology and Oncology and a member of the Harold C.  Simmons Comprehensive  Cancer Center.


        The KRAS gene produces K-Ras proteins that influence when cells divide. Mutations in K-Ras can result in normal cells dividing uncontrollably and turning cancerous.


        “Mutant KRAS not only promotes the growth of tumors, but also the survival of established lung cancer. Since we have no clinically relevant effective inhibitors of mutant KRAS at this time, there has been an intense clinical interest in developing a treatment that is proven effective,” said Dr. Scaglioni, who leads the Cancer Signaling Laboratory at the Simmons Cancer Center.


        The team found that the enzymatic activity of ACSL3 (Acyl-CoA synthetase long-chain family member 3) is needed for the mutant KRAS gene to promote the formation of lung cancer, and further demonstrated that fatty acids, which are the substrates of ACSL3 enzyme, have a critical role in lung cancer.


    “There is an urgent need for discovery of additional targets that inhibit lipid metabolism in cancer cells that could lead to targeted therapies: the discovery of the importance of ACSL3 in lung cancer meets this unmet need,” said Mahesh S. Padanad, Ph.D., first author and part of the University of Texas Southwestern team.

Relevant newsRelevant news